In a preclinical study, TWIST1 overexpression resulted in erlotinib and osimertinib resistance in EGFR-mutant NSCLC cells; conversely, genetic and pharmacological inhibition of TWIST1 increased the sensitivity to EGFR TKIs [83]. This evidence concerns the gene TWIST1 and non-small cell lung carcinoma.